Rituximab: a potential therapeutic advance in scleroderma: what is the evidence?
Simms
Robert W
RW
Lafyatis
Robert
R
D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008212:Lymphocyte Depletion / Q000379:methods; D000069283:Rituximab; D012595:Scleroderma, Systemic / Q000188:drug therapy* / Q000276:immunology
D058846:Antibodies, Monoclonal, Murine-Derived; D007166:Immunosuppressive Agents; D000069283:Rituximab